PALI (Palisade Bio Inc.) שולי רווח גולמי

Concentration risks on a single drug and a capital deficit are driving high volatility for Palisade Bio, Inc. (PALI). The gross margin history on the GURU.Markets terminal chart shows that the parameter value is -0.40. The company's revenues are based on the therapy of postoperative adhesions, while the stability of supply chains to clinics is ensured by specialized pharmaceutical logistics that minimize transportation losses.
פילוחי מדדים פיננסיים ומדדי שוק עבור Palisade Bio, Inc. (PALI)

Palisade Bio, Inc. (PALI) focuses on developing innovative therapeutics for gastrointestinal regeneration and the treatment of intestinal inflammation. Within this business model, the calculation model accounts for the difference between revenues and direct development costs to determine internal production efficiency. An analysis of the gross margin from sales allows for an assessment of the company's ability to convert revenue into profit before accounting for operating expenses.